Loading...
Low-dose ofatumumab for rituximab-resistant nephrotic syndrome
Drug resistant idiopathic nephrotic syndrome (DRNS) remains a therapeutic dilemma. In this pilot study, the efficacy of the new fully humanised, anti-CD20 monoclonal antibody ofatumumab was tested in 4 children with persistence of proteinuria for at least 12 months in spite of a full drug approach (...
Na minha lista:
| Udgivet i: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4577716/ https://ncbi.nlm.nih.gov/pubmed/26376698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2015-210208 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|